Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Insightful Analysis of Amgen Inc's Strengths, Weaknesses, Opportunities, and Threats
Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen ‘very encouraged’ by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year.